Date: 2015-01-15
Type of information: Nomination
Compound:
Company: Seres Therapeutics (USA - MA)
Therapeutic area: Metabolic diseases - Digestive diseases - Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On January 15, 2015, Seres Health announced the appointment of Michele (Shelley) Trucksis, Ph.D., M.D., as Executive Vice
President and Chief Medical Officer. In this role, Dr. Trucksis will be responsible for overseeing the clinical development
and operations of Seres\' Ecobiotic® product pipeline.
Dr. Trucksis has over twenty-five years of infectious disease-focused clinical research and medical experience. Prior to joining Seres, Dr. Trucksis served as Executive Director of Merck Research Laboratories with responsibility for medical, clinical and global product development functions and development strategy in antibacterials, antifungals and cytomegalovirus infections. Dr. Trucksis held various positions at Merck including Project Team Leader, Infectious Diseases and Director of Clinical Pharmacology. Previously, she was Deputy Editor, Infectious Disease at UpToDate, Inc., Director, Infectious Diseases Fellowship Program at the University of Massachusetts Medical School and Medical Officer at the Food Safety Inspection Service/USDA.
Dr. Trucksis received her M.D. from Case Western Reserve University, Ph.D. in Biochemistry from Kent State University and B.S. in Medical Technology from Youngstown State University. After her residency in internal medicine at Yale-New Haven Hospital, Dr. Trucksis completed fellowships in infectious diseases at Massachusetts General Hospital and bacterial pathogenesis at the University of Maryland Center for Vaccine Development.
Financial terms:
Latest news:
